VALLEY COTTAGE, New York, September 6 XTLBiopharmaceuticals Ltd. (NASDAQ: XTLB, LSE: XTL, TASE: XTL) announced todaythat a late breaker abstract, entitled "Potent Small Molecule HCV InhibitorsAffecting NS5A-dependent Functions," was selected for oral presentation atthe 14th International Symposium on Hepatitis C Virus & Related Viruses(http://www.hcv2007.com/).
The presentation will take place at 10:30 Greenwich Mean time onThursday, September 13, 2007, and a press release outlining the datapresented will be released by the Company shortly thereafter.
The compounds that will be presented at the conference emerged from theCompany's DOS program, aimed at discovering novel hepatitis C inhibitorsapplying a unique chemistry technology called Diversity Oriented Synthesis.The DOS program was acquired by the Company in late 2005.
ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development oftherapeutics for the treatment of neuropathic pain and hepatitis C. XTL isdeveloping Bicifadine, a serotonin and norepinephrine reuptake inhibitor, forthe treatment of diabetic neuropathic pain. XTL is also developing severalnovel pre-clinical hepatitis C small molecule inhibitors. XTL also has anactive in-licensing and acquisition program designed to identify and acquireadditional drug candidates. XTL is publicly traded on the NASDAQ, London, andTel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).Contact: Ron Bentsur Chief Executive Officer Tel: +1-845-267-0707 ext. 225
SOURCE XTL Biopharmaceuticals Ltd